- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
NEW YORK Cases of the potentially deadly skin cancer melanoma are expected to almost double before the end of the decade, according to a new report by research firm Datamonitor.
Research by the company indicated that cases of melanoma could go from the 138,000 new cases expected this year to 227,000 by 2019.
“There is real opportunity for drug developers willing to invest in this market,” Datamonitor senior healthcare analyst Tom Gray said. “A significant unmet need remains for more effective drugs, which makes melanoma a popular research target.”
Current cytokines and cytotoxics have response rates of up to 25%, according to the report, which results in the high mortality rate associated with metastatic melanoma, and no breakthroughs with the drugs have been made in the last 30 years. But several treatments are in the pipeline, including Medarex’s and Bristol-Myers Squibb’s MDX-010 (ipilimumab) and PLX-4032, by Roche and Plexxikon.